UPDATE: J.P. Morgan Reiterates Overweight Rating, Raises PT on Aegerion Pharmaceuticals

In a report published Monday, J.P. Morgan & Co. reiterated its Overweight rating on Aegerion Pharmaceuticals (NASDAQ: AEGR ), and raised its price target from $28.00 to $30.00. J.P. Morgan noted, “We are reiterating our OW rating on AEGR following FDA approval of Juxtapid (lomitapide) for HoFH, a potentially fatal